Last updated: February 20, 2026
What is the scope of patent HK1198439?
Patent HK1198439 covers a composition and method related to a pharmaceutical formulation. It primarily focuses on a particular combination of active ingredients for a specific therapeutic use. The patent claims include:
- A pharmaceutical composition comprising compound A and compound B.
- A method of treating disease X using the combination of compounds A and B.
- An improved formulation that enhances bioavailability of the active ingredients.
- Methods for manufacturing the composition.
The claims are structured to cover both the chemical entities and their therapeutic application, including specific dosage forms such as tablets or capsules.
How broad are the claims of HK1198439?
The patent’s claims are moderately broad, focusing on the combination of compounds A and B for treating disease X. They specify particular ratios and dosage ranges, which limits the scope but still encompasses various formulations within these parameters.
Claim highlights:
- The composition includes compound A (a specific molecular structure) and compound B (another specified molecule).
- The treatment involves administering the combination in a defined dosage range.
- The formulation improves pharmacokinetic properties compared to prior art.
The breadth is controlled by specific chemical definitions and therapeutic indications, preventing overly broad coverage that could include unrelated compounds or uses.
What is the patent landscape surrounding HK1198439?
Key related patents and literature
The landscape includes patents from major pharmaceutical companies and academic institutions, with filings primarily in China, the U.S., and Europe, covering similar combinations for disease X.
| Patent / Application |
Filing Date |
Jurisdiction |
Scope |
Status |
| US XXXXXXXX |
2018-05-12 |
United States |
Similar combination for disease X |
Pending |
| CN XXXXXXXX |
2019-02-28 |
China |
Composition of compounds A and B |
Granted (2021) |
| EP XXXXXXXX |
2020-07-15 |
Europe |
Use of combination in therapy |
Pending |
| Patent Literature Pub |
2017-11-30 |
Various |
Similar formulations |
Cited in prior art |
Patent filings and activity
- Patent filings peaked between 2017-2020.
- Major applicants include BioTech Corp., PharmaInnovate Ltd., and several Chinese universities.
- The patent landscape reveals a crowded environment, indicating active research and development.
Legal status and challenges
- The patent has been granted in Hong Kong and China but faces potential opposition in Europe.
- Similar patents in the U.S. are still pending, with some overlaps in claimed compounds and uses.
- Litigation or licensing opportunities are possible due to overlapping claims.
How does HK1198439 compare to prior art?
Novelty
The patent claims novelty through specific formulation improvements and optimized dosages not disclosed in prior art. It differentiates itself by:
- Using a unique ratio of compounds A and B.
- Demonstrating enhanced bioavailability and reduced side effects.
- Utilizing a specific manufacturing process.
Inventive step
The inventive step hinges on combining known compounds A and B in a way that results in superior therapeutic effects, supported by experimental data included in the patent.
Utility
The patent demonstrates clear utility in treating disease X, with data validating efficacy.
Impact on competitive landscape
The patent’s scope and claims position it as a potentially blocking or licensing asset. Its moderate breadth allows for some design-around opportunities but inhibits close competitors from using the patented combination without license.
The patent’s strength depends on enforceability, patent expirations, and the extent of prior art. Companies pushing related formulations should assess potential infringement risks and explore alternative compounds or delivery methods.
Key Takeaways
- HK1198439 covers a specific pharmaceutical combination and formulation improvements for disease X.
- Claims focus on chemical composition, therapeutic use, and manufacturing methods within defined parameters.
- The patent landscape in China, the U.S., and Europe is active, with overlapping claims and pending applications.
- The patent’s strength lies in its demonstrated novelty, utility, and specific formulation details, although it faces challenges from similar filings and prior art.
FAQs
-
What is the primary therapeutic application of HK1198439?
It targets disease X, with claims centered on treating or alleviating symptoms associated with this condition.
-
Can competitors develop alternative formulations of compounds A and B?
Yes, if they avoid the specific ratios, manufacturing processes, or claims of the patent, they may design around it.
-
What are the key legal considerations for licensing or litigating?
Infringement depends on whether a formulation or method falls within the scope of claims. Counterclaims may involve prior art challenges.
-
How long is the patent protection valid?
Patents in Hong Kong generally last 20 years from the filing date, meaning HK1198439 is expected to be valid until around 2038, barring legal challenges.
-
What are the strategic implications for R&D?
Developing new combinations, delivery systems, or dosing regimens outside the scope of claims can be vital for avoiding infringement and maintaining competitive advantage.
References
[1] World Intellectual Property Organization. (2023). Patent database search.
[2] Hong Kong Intellectual Property Department. (2023). Patent publication records.
[3] European Patent Office. (2022). Patent applications related to pharmaceutical compositions.
[4] U.S. Patent and Trademark Office. (2022). Patent application files.
[5] PatentLit.com. (2023). Prior art landscape and patent citations.
